Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kohjin Bio Co., Ltd. (177A.T)
Sakado, JP
Kohjin Bio Co., Ltd., established in 1981 in Sakado, Japan, and known as Kohjin Co.,Ltd. until its rebranding in 1989, is a diversified life science enterprise. The company's core business involves the production and sale of various biological materials, including animal blood, sera, cell culture media, agar media for microbial assays, in-vitro diagnostic products, and cosmetics. Its extensive catalog for cell and tissue culture features specialized mediums crucial for virus and recombinant protein synthesis, hybridoma development, human lymphocyte cultivation, and insect cell lines. Additionally, Kohjin Bio supplies complementary items such as gas-permeable cell culture bags, cryopreservation agents, medium supplements, normal human cells along with their growth media, ES cell media, and comprehensive kits for in-vitro fertilization and early embryo culture. The firm further provides essential laboratory tools like cell separation solutions, physiological salt solutions, and a range of research reagents. Within microbiology, Kohjin Bio offers a wide array of culture media tailored for various applications. For clinical diagnostics, this includes mediums for identifying gram-positive cocci and gram-negative bacteria, susceptibility testing, general differentiation, anaerobic growth, and fungal detection, alongside tube mediums for confirmatory tests and expansion. For food safety, their products cover sterilization assessments, and the detection of E. coli, coliform bacteria, Staphylococcus spp., Bacillus cereus, and Vibrio parahaemolyticus. The company also produces mediums for total viable cell count determination and specific media for Campylobacter and fungi. The company's blood and serum division offers normal human blood, serum, and plasma, as well as pathological human serum. Its animal blood portfolio encompasses preserved, defibrinated, and hemolyzed animal blood, in addition to animal serum and plasma, with custom-designed formulations like Eagle medium also available. Beyond its manufacturing activities, Kohjin Bio engages in the breeding and distribution of laboratory animals, the sale of medical equipment, and provides contract services for animal immunization and antibody preparation. The company also manages the import and export of its diverse products and raw materials internationally.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -20.66% | -31.49% | -25.55% | -15.29% | -35.54% | -29.88% | -39.71% | -57.22% | -57.22% | -57.22% | -57.22% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%-5.1% Q1'26: -10.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-68.4% Q1'26: -110.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+8.1% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+6.9% ★ Q1'26: -4.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+4.6% ★ Q1'26: -2.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.97× ★ Q1'26: 9.86× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. |
|---|---|---|---|---|
| Revenue |
4.77B
est: 4.72B (+1.0%)
|
5.21B
est: 4.72B (+10.4%)
|
5.13B
5.13B – 5.13B
+8.8% YoY
|
5.58B
5.58B – 5.58B
+8.7% YoY
|
| EBITDA |
958.10M
est: 1.26B (-23.8%)
|
1.41B
est: 1.15B (+22.8%)
|
1.25B
1.25B – 1.25B
+8.8% YoY
|
1.35B
1.35B – 1.35B
+8.7% YoY
|
| EBIT |
658.47M
est: 1.01B (-34.5%)
|
1.05B
est: 868.54M (+20.4%)
|
944.59M
944.59M – 944.59M
+8.8% YoY
|
1.03B
1.03B – 1.03B
+8.7% YoY
|
| Net Income |
384.00M
est: 354.66M (+8.3%)
|
794.76M
est: 636.39M (+24.9%)
|
683.42M
683.42M – 683.42M
+7.4% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
-1.0K
est: 615.17M (-100.0%)
|
—
est: 780.92M (-100.0%)
|
849.29M
849.29M – 849.29M
+8.8% YoY
|
922.96M
922.96M – 922.96M
+8.7% YoY
|
| EPS |
92.20
est: 69.40 (+32.9%)
|
155.52
est: 124.50 (+24.9%)
|
133.70
133.70 – 133.70
+7.4% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gen Akashi | Head of Internal Audit & Executive Officer | — | — |
| Kenji Hirata | Senior Executive Officer & Chief Administration Officer | — | — |
| Takahito Nakamura | President & Chairman | — | male |
| Yuichi Nakmura | Senior MD, GM of Sales & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 177A.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
